In re­ver­sal, NICE backs Rubra­ca af­ter Clo­vis agrees to a price cut

NICE has changed its mind, agree­ing to cau­tious­ly en­dorse Clo­vis On­col­o­gy’s Rubra­ca af­ter the drug­mak­er agreed to cut its price — about two months af­ter the UK cost-ef­fec­tive­ness agency’s ini­tial re­jec­tion.

Rubra­ca, known chem­i­cal­ly as ru­ca­parib, is ap­proved for use in the EU as monother­a­py for the main­te­nance treat­ment of adult pa­tients with high-grade ep­ithe­lial ovar­i­an, fal­lop­i­an tube, or pri­ma­ry peri­toneal can­cer who have re­lapsed af­ter plat­inum-based chemother­a­py.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER